|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
N/A |
Shares
Out: |
61,150,000 |
Market
Cap: |
6.68(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$113.49 - $145.93 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
3,704 |
4,538 |
27,327 |
209,575 |
Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$30,724,059 |
Total People Sold |
1 |
3 |
13 |
19 |
Total Sell Transactions |
2 |
4 |
21 |
80 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gala Renee D |
President & COO |
|
2024-04-05 |
4 |
D |
$115.21 |
$200,005 |
D/D |
(1,736) |
55,357 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2024-03-07 |
4 |
S |
$116.98 |
$206,821 |
D/D |
(1,768) |
6,596 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2024-03-06 |
4 |
S |
$117.51 |
$231,628 |
D/D |
(1,936) |
8,364 |
|
- |
|
Iannone Robert |
EVP, Global Head of R&D |
|
2024-03-05 |
4 |
D |
$117.53 |
$504,674 |
D/D |
(4,294) |
62,226 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2024-03-05 |
4 |
D |
$117.53 |
$403,363 |
D/D |
(3,432) |
41,629 |
|
- |
|
Pearce Samantha |
SVP, Head of Europe & Internat |
|
2024-03-05 |
4 |
D |
$117.53 |
$290,769 |
D/D |
(2,474) |
16,922 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2024-03-05 |
4 |
D |
$117.53 |
$2,636,903 |
D/D |
(22,436) |
429,809 |
|
- |
|
Gala Renee D |
President & COO |
|
2024-03-05 |
4 |
D |
$117.53 |
$425,694 |
D/D |
(3,622) |
57,093 |
|
- |
|
Gala Renee D |
President & COO |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,916 |
60,715 |
|
- |
|
Pearce Samantha |
SVP, Head of Europe & Internat |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,065 |
19,396 |
|
- |
|
Iannone Robert |
EVP, Global Head of R&D |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,928 |
66,520 |
|
- |
|
Cozadd Bruce C |
Chairman & CEO |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,187 |
452,245 |
|
- |
|
Kennedy Patrick |
Director |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,423 |
1,423 |
|
- |
|
Johnson Philip L |
EVP & Chief Financial Officer |
|
2024-03-01 |
4 |
B |
$119.65 |
$1,435,800 |
D/D |
12,000 |
27,932 |
2.74 |
- |
|
Johnson Philip L |
EVP & Chief Financial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,932 |
15,932 |
|
- |
|
Patil Neena M |
EVP & Chief Legal Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,348 |
45,061 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,987 |
10,300 |
|
- |
|
Henderson Mary Elizabeth |
SVP, Technical Operations |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,178 |
15,941 |
|
- |
|
Iannone Robert |
EVP, Global Head of R&D |
|
2024-01-17 |
4 |
D |
$119.13 |
$206,095 |
D/D |
(1,730) |
49,592 |
|
- |
|
Iannone Robert |
EVP, Global Head of R&D |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,970 |
51,322 |
|
- |
|
Gala Renee D |
President & COO |
|
2024-01-17 |
4 |
D |
$119.13 |
$381,693 |
D/D |
(3,204) |
40,799 |
|
- |
|
Gala Renee D |
President & COO |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,079 |
44,003 |
|
- |
|
Pearce Samantha |
SVP, Head of Europe & Internat |
|
2024-01-17 |
4 |
D |
$119.13 |
$123,657 |
D/D |
(1,038) |
14,331 |
|
- |
|
Pearce Samantha |
SVP, Head of Europe & Internat |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,210 |
15,369 |
|
- |
|
Carr Patricia |
SVP, Chief Accounting Officer |
|
2024-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,327 |
7,363 |
|
- |
|
881 Records found
|
|
Page 1 of 36 |
|
|